title: [The immunogenic capacity of soluble "vaccinia" antigen (fractionated smallpox vaccine) administered simultaneously with inactivated typhoid vaccine and with purified and concentrated tetanus anatoxin].
abstract: In this study we have investigated the immune humoral response in the associated vaccination with smallpox, tetanus and typhoid fractionated vaccine (trivaccine) administered in two series at 1 month interval, by dermojet, in a group of young people of 18-20 years old. The results were comparatively estimated with those obtained in two groups of young people of the same age (control group), separately immunized with two components of the tri-vaccine: fractionated smallpox vaccine and tetanus toxoid, following-up the humoral response to the two vaccine components. It was find that, at the end of the surveillance period, similar results were obtained for the testing group and control group, the antibody titers (in geometric mean) presenting very close values: 1/1,140,463 for the testing group, and 1/1,053,583 for the control group against vaccinia component, and 1/1,86,880,586 for the testing group and 1/79,900,431 for the control group, against the tetanus component. The results obtained entitle us to propose this vaccination scheme for the vaccination practice.
authors.forename: R
authors.initials: R
authors.lastname: Mihăilescu
authors.forename: G
authors.initials: G
authors.lastname: Dimache
authors.forename: V
authors.initials: V
authors.lastname: Velea
authors.forename: C
authors.initials: C
authors.lastname: Stoean
authors.forename: M
authors.initials: M
authors.lastname: Croitoru
authors.forename: S
authors.initials: S
authors.lastname: Durbacă
authors.forename: N
authors.initials: N
authors.lastname: Chirescu
mesh_terms: D000293:Adolescent; D000328:Adult; D000907:Antibodies, Bacterial / Q000032:analysis; D000914:Antibodies, Viral / Q000032:analysis; D000917:Antibody Formation / Q000276:immunology; D000956:Antigens, Viral / Q000008:administration & dosage / Q000276:immunology*; D003017:Clostridium tetani / Q000276:immunology; D006386:Hemagglutination Tests; D006801:Humans; D007117:Immunization, Secondary; D007277:Injections, Jet; D012900:Smallpox Vaccine / Q000008:administration & dosage / Q000276:immunology*; D012995:Solubility; D013745:Tetanus Toxoid / Q000008:administration & dosage / Q000276:immunology* / Q000302:isolation & purification; D013997:Time Factors; D014436:Typhoid-Paratyphoid Vaccines / Q000008:administration & dosage / Q000276:immunology*; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000276:immunology; D014616:Vaccinia virus / Q000276:immunology*
chemical_list: D000907:Antibodies, Bacterial; D000914:Antibodies, Viral; D000956:Antigens, Viral; D012900:Smallpox Vaccine; D013745:Tetanus Toxoid; D014436:Typhoid-Paratyphoid Vaccines; D015164:Vaccines, Inactivated
vernacular_title: La capacité immunogène de l'antigène soluble "vaccinia" (vaccin fractionné antivariolique) administré simultanément avec le vaccin typhoïdique inactivé et avec l'anatoxine tétanique purifiée et concentrée.